IMC Immuron Limited
Financings ·
The 45,472,000 shares are sold to US investors through the company's at-the-market facility, according to a note in the filing. The filing names no lead manager or underwriter.
We have not published a story on Immuron yet. When there is news, it will appear here.
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for inflammatory mediated and infectious diseases. Its proprietary platform uses oral polyclonal immunoglobulins, which can target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces within the gastrointestinal tract. Its flagship product, Travelan, is sold in Australia, Canada and the United States, and in Australia it is indicated to reduce the risk of travelers' diarrhea. The company launched ProIBS in Australia in October 2025, an over-the-counter product for relief of symptoms of irritable bowel syndrome. Marketed product sales were A$7.7 million for fiscal year 2026, A$7.3 million for 2025 and A$4.9 million for 2024. Its two lead oral polyclonal antibody candidates are in clinical development for travelers' diarrhea and recurrent Clostridiodies difficile infection. The company also describes a collaboration on anti-infective programs with the U.S. Department of Defense and a strategy to broaden its polyclonal-based pipeline across several indications.
| Product or program | What it is | Stage |
|---|---|---|
| Travelan | Oral polyclonal antibody product for travelers' diarrhea, sold in several countries | marketed |
| ProIBS | Over-the-counter product for relief of irritable bowel syndrome symptoms | launched in Australia in October 2025 |
| Lead oral polyclonal antibody candidates | Candidates for travelers' diarrhea and recurrent C. difficile infection | clinical development |
Our latest story on this, dated Dec 4, 2025: "Immuron to issue 45,472,000 shares at AUD 0.07910 in placement". The story links the filing or release it is based on. Read the story.
Immuron Limited trades under the ticker IMC on ASX.
Immuron Limited is listed on ASX. Our directory also records these other listings: GETTEX:ANW; NASDAQ:IMRN.
The SEC Central Index Key (CIK) for Immuron Limited is 1660046. Its filings are on SEC EDGAR.
322,848,081 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-09-24.
Our directory records Immuron Limited under Australia.
Our directory classifies Immuron Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Immuron Limited is AU000000IMC7.
aibio.space lists Immuron Limited among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as C3.
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for inflammatory mediated and infectious diseases. Its proprietary platform uses oral polyclonal immunoglobulins, which can target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces within the gastrointestinal tract.
Travelan: Oral polyclonal antibody product for travelers' diarrhea, sold in several countries Stage: marketed.
ProIBS: Over-the-counter product for relief of irritable bowel syndrome symptoms Stage: launched in Australia in October 2025.
Our latest story on Immuron, dated Dec 4, 2025: "Immuron to issue 45,472,000 shares at AUD 0.07910 in placement". The 45,472,000 shares are sold to US investors through the company's at-the-market facility, according to a note in the filing. The filing names no lead manager or underwriter. Source.
SEC records list Immuron Limited's filer category as: Non-accelerated filer.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio